Cynata Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYYNF research report →
Price Chart
About the company
Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD). Beyond this, its development pipeline features CYP-004, currently in Phase III clinical trials for osteoarthritis, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds.
- CEO
- Kilian Kelly
- IPO
- 2015
- Employees
- 2
- HQ
- Cremorne, VIC, AU
Get TickerSpark's AI analysis on CYYNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $340.84K
- P/E
- -0.36
- PEG
- -0.03
- P/S
- 0.00
- P/B
- -8.45
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -607.23%
- ROIC
- 2072.95%
Latest fiscal year · YoY change
- Revenue
- $1.71M-9.2%
- Gross Profit
- $1.71M-9.2%
- Op Income
- $-7,261,826
- Net Income
- $-9,089,281+3.2%
- EPS
- $-0.04+16.2%
- OCF Growth
- +22.8%
- FCF Growth
- +23.2%
- 52W High
- $0.22
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.13
- Beta
- 1.12
- RSI (14)
- 3
- Avg Volume
- 85
No earnings-call transcripts are available for CYYNF yet.
- Free Float
- 78.4%
- Shares Outstanding
- 243.45M
- Float Shares
- 190.86M
Our CYYNF coverage
Recent articles, reports, and earnings notes.
No research on CYYNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYYNF report →Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
seekingalpha.com · Jun 21
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
seekingalpha.com · Feb 4
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
defenseworld.net · Jan 14
Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey
defenseworld.net · Dec 19
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
seekingalpha.com · Nov 8
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Aug 4
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
seekingalpha.com · Feb 5
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
seekingalpha.com · Feb 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.